Report Overview
The Global De-identified Health Data Market size is expected to be worth around US$ 26.7 Billion by 2035 from US$ 10.1 Billion in 2025, growing at a CAGR of 10.2% during the forecast period 2026-2035. In 2025, North America led the market, achieving over 38.5% share with a revenue of US$ 3.9 Billion.
The global de-identified health data market is witnessing significant growth as healthcare organizations, research institutions, pharmaceutical companies, and technology providers increasingly leverage anonymized patient information to drive innovation and improve outcomes. De-identified health data refers to medical information from which personal identifiers have been removed, enabling secure analysis while protecting patient privacy and complying with regulatory requirements.
Growing adoption of artificial intelligence, machine learning, real-world evidence studies, and precision medicine initiatives is fueling demand for high-quality healthcare datasets. These datasets help stakeholders identify disease trends, optimize clinical trials, accelerate drug development, and enhance population health management strategies. The expanding use of digital health platforms, electronic health records, and connected healthcare technologies is further contributing to market growth by generating large volumes of valuable health data.
North America currently leads the market due to advanced healthcare infrastructure, strong regulatory frameworks, and widespread adoption of health information technologies. Meanwhile, Asia-Pacific is emerging as a high-growth region, supported by increasing healthcare digitization and investments in data analytics capabilities.
Key market participants are focusing on strategic partnerships, data integration solutions, and advanced privacy-preserving technologies to strengthen their competitive position. As organizations seek to balance data accessibility with patient confidentiality, the de-identified health data market is expected to play a critical role in supporting healthcare research, innovation, and evidence-based decision-making across the global healthcare ecosystem.
Click here for more information: https://market.us/report/de-identified-health-data-market/
Key Takeaways
- The global de-identified health data market was valued at US$ 10.1 billion in 2025 and is anticipated to reach US$ 26.7 billion by 2035, registering a CAGR of 10.2% during the forecast period.
- By type, clinical data dominated the market, accounting for 19.6% of the total market share in 2025.
- Based on application, the clinical and medical research segment held the largest share, contributing 18.3% of the market revenue.
- Among end users, healthcare providers emerged as the leading segment, capturing 36.4% of the overall market share.
- North America remained the dominant regional market, representing 38.5% of the global market share due to its advanced healthcare e cosystem and extensive use of health data analytics. Key Market Segments By Type Clinical Data Demographic Data Administrative Data Unstructured Data Temporal Data Others By Application Clinical and Medical Research AI and Machine Learning Training Electronic Health Records (EHR) Data Sharing Healthcare Analytics and Marketing Public Health and Disease Surveillance Others By End User Healthcare Providers Pharmaceutical Companies Biotechnology Firms Medical Device Manufacturers Insurance Companies/ Healthcare Payers Research Institutions Government Agencies Other Top Key Players IQVIA Oracle (Cerner Corporation) Optum, Inc. (UnitedHealth Group) ICON plc Veradigm LLC IBM Premier, Inc. Shaip Komodo Health, Inc. Evidation Health, Inc. Medidata Clarify Health Solutions *Emerging Trends in the De-identified Health Data Market * Growing Use of Real-World Evidence: Healthcare organizations are increasingly using de-identified electronic health records (EHRs), claims data, and patient registries to generate real-world evidence. The U.S. FDA recognizes these data sources for evaluating treatment safety and effectiveness, helping accelerate regulatory and clinical decision-making processes.
Expansion of Large-Scale Health Data Platforms: Government-backed health databases are expanding rapidly. The NIH All of Us Research Program has enrolled nearly 850,000 participants, creating one of the world's largest diverse health datasets. Such initiatives are increasing the availability of de-identified data for healthcare research and innovation.
Rising Adoption of AI and Machine Learning: AI developers are increasingly relying on de-identified healthcare datasets to train predictive models and clinical decision-support tools. In 2026, the FDA launched AI-enabled initiatives to monitor clinical trials, with expectations of reducing trial timelines by 20%–40% through advanced data analytics.
Increased Public Health Surveillance Activities: Public health agencies are leveraging de-identified datasets to detect outbreaks and monitor disease patterns. According to the CDC, de-identified disease surveillance data is routinely used to support outbreak identification, disease tracking, and public health program evaluation across the United States.
Greater Availability of Government Health Data: Government agencies are improving access to healthcare datasets for research purposes. CMS provides data covering more than 160 million individuals through Medicare, Medicaid, CHIP, and Marketplace programs, significantly expanding opportunities for de-identified health data analysis and healthcare studies.
Key Use Cases of De-identified Health Data
Clinical and Medical Research: Researchers use de-identified patient records to study disease progression, treatment outcomes, and population health trends without exposing patient identities. This approach supports large-scale observational studies while maintaining compliance with healthcare privacy regulations.
Drug Discovery and Regulatory Submissions: Pharmaceutical companies utilize de-identified real-world data to identify patient populations, assess treatment effectiveness, and support regulatory submissions. The FDA increasingly accepts real-world evidence derived from EHRs, claims data, and registries in drug development programs.
AI Model Training and Predictive Analytics: De-identified healthcare datasets are widely used to train artificial intelligence algorithms for disease prediction, risk assessment, and clinical decision support. Access to large anonymized datasets improves model accuracy while minimizing privacy risks associated with patient information.
Population Health and Disease Monitoring: Public health organizations analyze de-identified health information to monitor disease prevalence, identify emerging health threats, and evaluate intervention programs. CDC surveillance systems routinely use de-identified data to track national notifiable diseases and public health trends.
**Healthcare Quality and Operational Improvement: **Hospitals, payers, and healthcare systems use de-identified datasets to measure treatment outcomes, optimize resource allocation, and improve patient care quality. CMS data resources covering over 160 million beneficiaries support healthcare performance benchmarking and policy evaluation activities.
Conclusion: The global de-identified health data market is expected to experience significant growth, increasing from US$ 10.1 billion in 2025 to US$ 26.7 billion by 2035 at a CAGR of 10.2%. Rising adoption of artificial intelligence, real-world evidence studies, and data-driven healthcare strategies is driving demand for secure and privacy-compliant health datasets. Clinical research, drug development, healthcare analytics, and population health management remain key application areas. North America leads the market due to its advanced healthcare infrastructure, while Asia-Pacific is emerging as a high-growth region. Continued advancements in data privacy and interoperability will further support market expansion and innovation.
Top comments (0)